Technical Assistance CPP participants could leverage other Navy initiatives, such as the Navy Transition Assistance Program (TAP), which culminated with a technology showcase and presentations at the Navy Opportunity Forum
Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection
Supraorbital block (in the forehead and eye socket): Lessens or eliminates pain from burns and other injuries, as well as migraines and other types of headaches with injections near the eyebrows
Sources: Neelakantan et al., Biochem Pharmacol 2018 | Dimet-Wiley et al., Sci Rep 2024 Security Profile & Chemical Identity Molecular specifications and preclinical safety data 5-Amino-1MQ Chemical Identity A small molecule derived from quinolinium salts, developed at the University of Texas (2017) 5-Amino-1MQ Tolerance & Status Safety data from preclinical studies (DIO mouse model) Published Preclinical Data 3 key studies published in Biochemical Pharmacology and Scientific Reports 35% Reduction of white adipose tissue in 11 days (20 mg/kg, 3 times/day) Physical Effects (11 days) + 40 % Improvement of grip strength in aged mice (22-24 months) Strength & Performance (aged mice) microbiome The combination of 5-Amino-1MQ + caloric restriction establishes a distinct gut microbial profile Protocol & Results Important Notice Search Only Not intended for human consumption
Evidence-Base Disclosure The published evidence base for AOD-9604 consists predominantly of preclinical research animal models (often rats or mice) and in vitro cell-culture experiments
